Clinical trials: Breast Cancer Risk, active
Breast Cancer, Breast Cancer Female
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer in women with dense breast tissue by studying changes that occur in breast tissue and blood as a result of participating…
- Trial name
- NCT06322888
- Testing
- Exercise Training Program
- Where
- 2 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
The goal of this observational study is to develop and validate an artificial intelligence (AI) model for predicting the risk of distant metastasis in patients with primary breast cancer.
- Trial name
- ARGUS project (NCT07244094)
- Testing
- Diagnostic Test: AI-Based Spatial Pathomic Analysis
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer Risk, Cardiovascular Disease Risk
The RISC Registry--Risk Informed Screening Registry
Chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. Six in ten adults have one chronic disease; 4 in 10 have two or more.
- Conditions
- Breast Cancer Risk, Cardiovascular Disease Risk, Cardiometabolic Risk, Diabetes
- Trial name
- RISC (NCT05848856)
- Testing
- Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Precision Health Equity Initiative
Breast Cancer
Partial Breast Proton Therapy for Early Stage Breast Cancer
The purpose of this is to determine the efficacy and toxicity of proton therapy when used to deliver partial breast radiotherapy in patients with early stage breast cancer with low or intermediate risk factors.
- Trial name
- NCT01310530
- Testing
- Proton Beam Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Loma Linda University
Breast Cancer
Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer
The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast…
- Trial name
- NCT04517266
- Testing
- omit of IMI group, IMI group
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Ruijin Hospital
Cancer, Breast, Age-related Cognitive Decline
Older Breast Cancer Patients: Risk for Cognitive Decline
The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and…
- Conditions
- Cancer, Breast, Age-related Cognitive Decline, Cognitive Decline
- Trial name
- TLC (NCT03451383)
- Where
- United States
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Breast Cancer, Breast Cancer Female
Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer
Surveillance and aftercare for curatively treated primary breast cancer patients is currently mostly 'one-size-fits-all', but can be personalized based on patients' risk of recurrence (depending on patient-, tumor- and…
- Conditions
- Breast Cancer, Breast Cancer Female, Survivorship
- Trial name
- NABOR (NCT05975437)
- Testing
- personalized surveillance plans (PSP) and personalized aftercare plans (PAP)
- Where
- 10 sites in Netherlands
- Volunteers
- 1,040 people
- Sponsor
- Comprehensive Cancer Centre The Netherlands
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
High Risk for Invasive Breast Cancer
SHORTened Duration of TAMoxifen
The purpose of this study is to learn whether a shorter-duration, low-dose tamoxifen regimen can reduce the risk of developing breast cancer or breast cancer recurrence in post-menopausal women who are at increased risk for…
- Trial name
- NCT07806630
- Testing
- Tamoxifen, Tamoxifen (Nolvadex)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer Risk
Uptake of Genetic Counseling Among African American Women
A feasibility study incorporating an educational intervention with cancer genetic risk assessment (CGRA) in the UI Health mammography center
- Trial name
- NCT04082117
- Testing
- Educational video
- Where
- 2 sites in United States
- Volunteers
- 960 people
- Sponsor
- University of Illinois Chicago
Breast Cancer, Breast Cancer Stage II
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- BRINK (NCT07188246)
- Testing
- Radiation, Pembrolizumab (KEYTRUDA®)
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Breast Cancer
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA
CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
- Trial name
- GALIA (NCT07418125)
- Testing
- Liquid biopsy
- Where
- Slovenia
- Volunteers
- 130 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer
Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability
Our objective is based on a personalized approach of adjuvant breast radiotherapy by selecting patients according to tumor recurrence and toxicity risk.
- Trial name
- PROBA (NCT06382818)
- Testing
- COHORT A, COHORT B, COHORT C
- Where
- France
- Volunteers
- 854 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Atypical Hyperplasia, Breast Carcinoma
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05941520
- Testing
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Behavior, Risk
Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult Women
This randomized trial aims to test the effects of co-created breast cancer counter marketing intervention messages for reducing alcohol consumption and impacting awareness and beliefs about the breast cancer risks from alcohol…
- Trial name
- B-Track (NCT07320664)
- Testing
- Alcohol and Breast Cancer Risk Messages, Skin Cancer Risk Messages
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Early-Stage Breast Cancer, Neoadjuvant Therapy
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients.
- Trial name
- COGNITION (NCT05906407)
- Testing
- Genomic Profiling / Sequencing
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- German Cancer Research Center
Breast Cancer, Colorectal Cancer
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families to genetic testing and counseling so that they can know their cancer…
- Trial name
- NCT05694559
- Testing
- Genetic Testing and Counseling, Screening Form
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of…
- Trial name
- NCT03725059
- Testing
- Pembrolizumab (K), Paclitaxel (X), Doxorubicin (A)
- Where
- 244 sites in United States, Australia and 22 more
- Volunteers
- 1,240 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer Metastatic, Breast Cancer Stage IV
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the…
- Trial name
- SAFIR3LibHERty (NCT06680596)
- Testing
- trastuzumab derxutecan
- Where
- 40 sites in France
- Volunteers
- 80 people
- Sponsor
- UNICANCER